drugset / Trial / NCT00313287
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine safety and efficacy of 30 mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in patients with chronic HBV.
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2004-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clevudine | Small molecule | 30 mg | — |